News - Targacept

Filter

Current filters:

Targacept

Popular Filters

Targacept trial does not show superiority of TC-1734 over donepezil

Targacept trial does not show superiority of TC-1734 over donepezil

15-07-2014

US-based clinical-stage biopharma company Targacept has announced results from a Phase IIb monotherapy…

Alzheimer's diseaseDonepezilNeurologicalPharmaceuticalResearchTargaceptTC-1734USA

Retrophin pulls out of deal to acquire Transcept Pharmaceuticals

17-12-2013

USA-based Retrophin says it has withdrawn its unsolicited offer to acquire all the shares of Transcept…

Mergers & AcquisitionsPharmaceuticalRetrophinTargacept

Targacept to drop development of TC-5619 in schizophrenia, after disappointing trial results

17-12-2013

Shares of US biopharma drug developer Targacept tanked nearly 33% to $4 in pre-market trading on December…

NeurologicalPharmaceuticalResearchTargaceptTC-5619

Targacept regains rights to Alzheimer's drug candidate from AstraZeneca

06-03-2013

US biopharma drug developer Targacept (Nasdaq: TRGT) and Anglo-Swedish drug major AstraZeneca (LSE: AZN)…

AstraZenecaAZD1446LicensingNeurologicalPharmaceuticalResearchTargaceptTC-1734

Senior appointments at Sanofi, Shire and Targacept; Global Fund names new executive director, fires inspector general

16-11-2012

French drug major Sanofi (Euronext: SA) has appointed Gary Nabel, as senior vice president, chief scientific…

ManagementPharmaceuticalSanofiShireTargacept

Targacept ADHD candidate fails to meet primary endpoints in Ph II study

18-09-2012

In a second disappointment this year, US drug developer Targacept (Nasdaq: TRGT) said yesterday that…

BiotechnologyNeurologicalPharmaceuticalResearchTargaceptTC-5619

Targacept to drop TC-6987 in diabetes on mixed trial results

28-03-2012

US drug developer Targacept (Nasdaq: TRGT) saw its shares drop 5% to $5.12 ,after the company announced…

DiabetesPharmaceuticalResearchRespiratory and PulmonaryTargacept

Astra Zeneca abandons TC-5214 regulatory filing as Ph III fails

20-03-2012

In what is another pipeline disappointment for the company, Anglo-Swedish drug major AstraZeneca (LSE:…

AstraZenecaNeurologicalPharmaceuticalRegulationResearchTargacept

Double R&D setback for AstraZeneca; new deal for cancer candidate

21-12-2011

Anglo-Swedish drug major AstraZeneca (LSE: AZ) had a double dose of bad news, when the company said that…

Hutchison MediPharmaLicensingNeurologicalolaparibOncologyPharmaceuticalResearchTargaceptvolitinib

Disappointment for AstraZeneca and Targacept as antidepressant fails to meet Ph III endpoint

09-11-2011

Anglo-Swedish drug major AstraZeneca (LSE: AZN) and Targacept (Nasdaq: TRGT) yesterday reported disappointing…

AstraZenecaNeurologicalPharmaceuticalResearchTargacept

Targacept gets AstraZeneca milestone on Alzheimer’s collaboration

12-10-2011

US drug developer Targacept (Nasdaq: TRGT) says it has initiated a potential registration study of AZD3480…

AstraZenecaLicensingNeurologicalPharmaceuticalResearchTargacept

Back to top